Mycobacterium leprae synthesizes large quantities of a specific phthiocerol-containing phenolic glycolipid in vivo. We had shown earlier that viable M. leprae readily incorporates radiolabeled palmitic acid into phenolic glycolipid I when residing in cultured macrophages in vitro and that this process is inhibited by the antileprosy drug rifampin. In the present paper we report the application of this observation to the rapid evaluation of over 25 antimicrobial agents for potential antileprosy activity in vitro. All the known antileprosy drugs rifampin, dapsone, clofazimine, and ethionamide inhibited phenolic glycolipid I synthesis. Rifabutin, a spiropiperidyl derivative of rifamycin, also reported to be active in the mouse model, was very effective. Interestingly, the macrolides erythromycin, clarithromycin, and roxithromycin were also found to be active in this system, while D-cycloserine and other cell wall synthesis inhibitors showed no effect. Many of the compounds found to be active in this system have been reported to be effective in vivo in mice. This correlation lends support to the feasibility of using phenolic glycolipid I synthesis for the rapid evaluation of new drugs against leprosy.
feasibility of using phenolic glycolipid I synthesis for the rapid evaluation of new drugs against leprosy.
The increased emergence of drug-resistant strains of Mycobacterium leprae in recent years has emphasized the need to identify new compounds effective in the treatment of leprosy. Since M. leprae does not multiply in vitro, conventional microbiological assays cannot be used for primary evaluations of new drugs for antileprosy activity. Prior to 1960, antileprosy drugs were selected primarily on the basis of empirical results of clinical trials with leprosy patients. The mouse footpad technique developed in 1960 by Shepard (38) proved to be an invaluable tool in the primary selection of new drugs by facilitating comparison of the bactericidal potency of different compounds and by making it possible to differentiate bactericidal activity from bacteriostatic effects. The activity of a drug in the mouse model is strongly correlated with its ultimate efficacy in humans. However, primary evaluation of new drugs by this approach has severe practical limitations since the assay is time-consuming (requires 4 to 8 months) and laborious, requires at least 4 to 5 g of a test compound for a test screening, and is heavily dependent on the compound's having favorable pharmacokinetics in the mouse. The development of a rapid and reliable in vitro drug-screening system would allow primary screening and selection of more compounds with potential antileprosy activity, the activity of which could then be tested in mice prior to clinical trials.
A number of in vitro metabolic assay systems have been reported in recent years, and these have been extensively reviewed (22, 47, 48) . These assays are based on the observation that M. leprae, although incapable of proliferation in vitro, retains many of its metabolic functions for a limited period of time outside the host either in tissue culture or in cell-free systems. The metabolism of the organism has been quantitated in terms of either its anabolic (3, 7, 21, 31, 35, 36) or catabolic (5) functions. The intracellular ATP content of M. leprae has also been used to determine the metabolic state of the organism (2, 27) and to screen compounds for antileprosy activity (8). In an earlier paper (36), we described * Corresponding author. an in vitro assay for quantitating the metabolic activity of M. leprae within mouse peritoneal macrophages based on the incorporation of radiolabeled palmitic acid ([U-'4C]PA) into its unique glycolipid antigen, phenolic glycolipid I (PGL-I). Since this assay measures the synthesis of a product specific to M. leprae (1, 24) , it eliminates interference due to metabolism of the host cell or that of other low-level contaminating bacteria which could be present in some M. leprae preparations. We demonstrated the inhibitory effects of the antileprosy drug rifampin on PGL-I synthesis and suggested the possible application of this technique to the primary evaluation of new drugs against leprosy (36) . Subsequently, M. leprae has been reported to incorporate [U-14C]PA into PGL-I when incubated in an axenic medium (7) , and the effect of a number of antimicrobial agents on PGL-I synthesis has been studied in this system (21) . In the present paper we report on the effect of different antimicrobial agents on the synthesis of PGL-I by M. Ieprae within mouse peritoneal macrophages in vitro.
[U-_4C]PA. [U-14CIPA (NEC 534; specific activity, 850 mCi/mmol) was obtained from New England Nuclear Research Products, Boston, Mass.
Bacteria. Viable leprosy bacteria were freshly harvested for all experiments from either the footpad tissues of experimentally infected athymic nude mice (athymic nulnu AF; Harlan Sprague Dawley Inc., Indianapolis, Ind.) or the lymph node tissues of experimentally infected armadillos. The bacteria were recovered from the tissues as described earlier (36) , suspended in RPMI 1640, and enumerated by the procedure of Shepard and McRae (43) .
Macrophages. Peritoneal cells were harvested from normal, unstimulated, female Swiss Webster mice (retired breeders; Simonsen Laboratories, Gilroy, Calif.) by methods described previously (26) . Briefly, the cells were harvested in cold Hanks balanced salt solution (HBSS) containing heparin (10 U/ml), washed by centrifugation at 150 x g for 10 min, and suspended in RPMI 1640 supplemented with fresh 1 mM glutamine (Irvine Scientific, Santa Ana, Calif.), 25 mM HEPES buffer (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), penicillin G (100 U/ml; Sigma Chemical Co.), and 20% heat-inactivated fetal calf serum (FCS) (Hyclone Sterile Systems, Inc., Ogden, Utah). Ten million peritoneal cells (approximately 50 to 55% macrophages) were plated in each 25-cm2 tissue culture flask (no. 25100; Corning Glass Works, Corning, N.Y.). The flasks were incubated overnight at 37°C in 5% CO2 in humidified air, and the nonadherent cells were removed by washing with warm HBSS.
Infection of the macrophage monolayer. The monolayers were overlaid with a 5-ml suspension of M. leprae (200 x 106 acid-fast bacilli) in RPMI 1640 containing 20% FCS (RPMI 1640-20% FCS) and incubated at 37°C in an atmosphere of 5% CO2 in humidified air. After 1 h, the nonphagocytized bacteria were removed by washing with warm HBSS, and the infected monolayers were reincubated with fresh medium in a humidified atmosphere of 5% CO2 in air at 37°C.
Quantitating drug activity. The infected macrophages were incubated with the drugs, and their effect on M. leprae metabolism was determined as described earlier (36) . Briefly, this involved incubating the drug-treated infected monolayers and the untreated controls for 4 days and then adding 1.0 ,uCi of [U-'4C]PA in RPMI-2.5% FCS and incubating for an additional 7 days in the presence or absence of the drug. At the termination of the experiment, the macrophage monolayers were lysed by the addition of 200 pAl of a solution containing 0.1% sodium dodecyl sulfate, 1% each sodium deoxycholate and Triton X-100, and 10 mM sodium chloride in 10 mM Tris hydrochloride buffer (pH 7.8). The lysates were subjected to brief sonication (-60 s) in an ultrasonic cleaner (no. B 2200-R-2; Bransonic Instruments, Shelton, Conn.) to reduce bacterial clumping, and the acidfast bacteria in each of the samples were enumerated by the method of Shepard and McRae (43) . The lysates were then autoclaved at 15 lb of pressure for 15 min and lyophilized. Autoclaving the samples did not affect the amount of radioactivity associated with the PGL-I fraction. Total lipids were then extracted from the lysates with a mixture of chloroform-methanol (2:1) at 55°C in a shaking water bath for 18 h, and the extract was subjected to biphasic partitioning as described earlier (36) . The lower organic phase, containing the glycolipids, was then fractionated on a column of Flori- sil-silicic acid (2:1) based on the procedure of Hunter and Brennan (24) . The eluted glycolipid fraction was analyzed by thin-layer chromatography with a solvent system of etheracetone (80:20) along with a known standard of PGL-I (provided by P. J. Brennan, Colorado State University, Fort Collins). The glycolipids were visualized by spraying the plate with a solution of 0.1% orcinol in 40% H2SO4, followed by heating at 110°C. The area on the thin-layer chromatography plate associated with the standard PGL-I was scraped off, and the radiolabel associated with it was measured in an LS-5801 liquid scintillation counter (Beckman Instruments, Inc., Fullerton, Calif.). Counts per minute were converted and normalized to disintegrations per minute per 108 acidfast bacteria. Percent inhibition of PGL-I synthesis was calculated by the following equation: percent inhibition = [(1 -dpm in PGL-I of treated samples)/(dpm in PGL-I of control samples)] x 100.
Statistical analysis. The data were analyzed by Student's t test. All probability determinations were two-tailed, and P < 0.05 was considered significant.
RESULTS
Optimization of in vitro conditions for the synthesis of labeled PGL-I by M. leprae in infected macrophages. The biosynthesis of PGL-I was compared at 33 and 37°C, temperatures thought to be optimum for the metabolism of M. leprae and macrophages, respectively (Fig. 1 integrity of the macrophage monolayers. Hence, in all the drug assays, the concentration of FCS in the medium was changed from 20 to 2.5% at the time of the addition of the labeled PA. Figure 3 shows the rates of synthesis of PGL-I in the macrophages over time. Infected monolayers were given 2-day consecutive pulses with [U-14C]PA. Active synthesis of PGL-I occurred throughout the period of 10 days.
Effect of antimicrobial agents on PGL-I synthesis. (i) Antileprosy drugs. The effects of several known antileprosy agents on PGL-I synthesis are presented in Table 1 . All the standard antileprosy drugs tested (dapsone, ethionamide, rifampin, and clofazimine) showed marked inhibition of PGL-I synthesis at concentrations of 2 ,ug/ml. Rifabutin (a spiropiperidyl derivative of rifampin) was active, whereas isoniazid did not show significant activity even at a concen- ited PGL-I synthesis at concentrations of 2 jig/ml (Table 1) , and significant inhibition was also noted at concentrations as low as 10 ng/ml (data not shown). Clofazimine and its two analogs, B 826 and B 3785, were equally effective in inhibiting PGL-I synthesis at concentrations of 2 jig/ml, but at lower concentrations (0.2 jig/ml), only clofazimine showed significant activity.
(ii) Effect of protein synthesis inhibitors. The effect of several antimicrobial agents which act by specifically inhibiting protein synthesis are shown in Table 2 . Both minocycline and erythromycin had significant activity at concentrations of 2 ,ug/ml. Tetracycline showed weak but significant activity (P < 0.05) at a concentration of 20 pg/ml. Erythromycin as well as two of its derivatives, clarithromycin and roxithromycin, inhibited PGL-I synthesis (>80%) at concentrations as low as 10 ng/ml (data not shown). The aminoglycoside streptomycin had no significant activity at 2 p.g/ml, although it was active at 20 ,ug/ml. Kanamycin and gentamicin had no significant effects at the concentrations tested. Both chloramphenicol and clindamycin were active at concentrations of 20 ,ug/ml.
(iii) Effect of other antimicrobial agents. None of the cell wall synthesis inhibitors examined (cloxacillin, cephalothin, and D-cycloserine) were active (Table 3) . Among the nucleic acid synthesis inhibitors tested, ciprofloxacin, a fluoroquinolone derivative of nalidixic acid, as well as nalidixic acid itself had significant activity at 20 p.g/ml. The cell membrane synthesis inhibitor polymyxin B was inactive, whereas the antifungal agent griseofulvin stimulated incorporation of the labeled PA into the glycolipid ( M. leprae remained metabolically active within these phagocytic cells in vitro for at least 10 days. No significant differences in the synthesis of PGL-I were observed at incubation temperatures of 33 and 37°C. This is in contrast to studies with the cell-free system (21) , in which the temperature optimum was 33°C and incubation temperatures of 37°C adversely affected PGL-I synthesis. The rate of intracellular ATP decay in M. leprae incubated in axenic medium has also been shown to be more rapid at an incubation temperature of 37°C than at 33°C (6) . It is likely that the temperature optimum for some of the synthetic enzymes of the bacteria is about 33°C. Thus, incubating the bacteria at higher temperatures could be inactivating these enzymes, thereby shutting down the synthesis of some of its essential metabolic requirements. Since the temperature optima for the macrophages are higher, these cells may be providing the bacteria with the essential metabolic requirements that it is incapable of synthesizing at the higher temperatures. A similar explanation has been given for the intracellular parasite Leishmania donovani (45) , which is also capable of surviving both in cell-free systems and within host cells. The optimum temperature for the growth of this pathogen in the cell-free system is reported to be about 25°C, and it is inhibited at an incubation temperature of 33°C. In the host cell in vitro, however, the pathogen is capable of proliferation at 37°C. The decreased incorporation of [U-14C]PA into PGL-I with increasing FCS levels in the medium is probably the result of serum fatty acids competing with the labeled substrate in this assay.
The antileprosy drugs rifampin, dapsone, clofazimine, and ethionamide inhibited PGL-I synthesis at relatively low concentrations (<2 ,ug/ml). The inhibitory effects of both dapsone and rifampin were apparent at concentrations as low as 10 nglml. At this concentration, dapsone, rifampin, and clofazimine are reported to inhibit the incorporation of [3H]thymidine by M. leprae residing in vitro within mouse peritoneal macrophages (32) (33) (34) . All these drugs are active in vivo in mice as well as in humans (22, (40) (41) (42) . Isoniazid was inactive in this system, although its mode of action is thought to be similar to that of ethionamide (49), i.e., inhibition of mycolic acid synthesis. In the cell-free system, however, isoniazid significantly inhibited PGL-I synthesis (21), although it had no effect on the ATP content of the M. leprae incubated in the same medium (8). In vivo, isoniazid is reported to be active in mice against some strains of M. leprae (41) and inactive against others (40) . In contrast, ethionamide was effective in our system at concentrations of 2 ,ug/ml, while its MIC against M. leprae in mice is reported to range from concentrations in serum of 0.2 ,ug/ml (15) to about 25 ,ug/ml (42) . In the cell-free system, ethionamide was shown to decrease the intracellular ATP content of M. leprae (8), although it was reported to enhance the synthesis of PGL-I in the same system (21) . Synthesis of PGL-I in the macrophages was inhibited by relatively low concentrations of rifabutin. Rifabutin is somewhat more potent than rifampin when tested in vitro against several cultivable strains of mycobacteria (50) and has been reported to be active against M. leprae in mice (23) . Although in the cell-free system both analogs of clofazimine, B3785 and B826, were more effective than clofazimine (8), the latter appeared to be more potent than the analogs in the present study. Relatively poor uptake of these analogs by the macrophages may account for their relatively low activity.
Although both streptomycin and kanamycin have been reported to be active against M. leprae in vivo in mice (13, 16, 39) , our studies indicated that streptomycin was active only at high concentrations (20 ,uglml) (46) and in vivo against M. marinum infections (30) . In a recent study, minocycline has been shown to about 99% bactericidal against M. leprae in vivo at a level of 0.04% in feed, equivalent to a level of 0.6 ,ug/ml in serum. Its MIC against M. leprae in experimental infections is reported to be about 0.2 ,ug/ml (14) . The increased potency of minocycline against mycobacteria is attributed to its highly lipophilic nature, which allows it to penetrate the lipid-rich outer layer of the organisms (4) . Minocycline was also shown to accelerate the intracellular ATP decay in M. leprae in the cell-free system (8), although interestingly, in the same system it stimulated the synthesis of PGL-I at lower concentrations (21) . Erythromycin has been reported to be ineffective against M. leprae in vivo (12) . Its apparent inactivity in vivo may be the result of its poor pharmacokinetics in the mouse (17) . It has been reported to be active against M. leprae in the cell-free system (8, 21), although the concentrations of erythromycin and the other macrolides required to inhibit the bacteria in the macrophages were observed to be much lower. The excellent penetration of macrolides into and their accumulation within phagocytes (20) may be responsible for their increased activity in this tissue culture system. The macrolide roxithromycin, apart from being bactericidal, has also been observed to enhance the phagocytic functions of polymorphonuclear leukocytes (28) . Clarithromycin has been recently shown to be active against M. leprae in vivo in mice, which is attributed to its relatively better pharmacokinetics in mice (9) . Although gentamicin was shown to inhibit the synthesis of PGL-I in the cell-free system (21) , it failed to show any effect in the macrophages. Gentamicin is poorly taken up by phagocytic cells (20) , and this probably accounts for its inactivity against M. leprae in the macrophages. Gentamicin has been reported to have no effect against M. leprae in animal experiments (16) . Although there are no reports on the activity of chloramphenicol on M. leprae in vivo, several other in vitro systems (8, 21, 25) , including that used in the present study, have shown it to be active. The lack of activity of polymyxin B in this system is consistent with in vivo (29) as well as in vitro (8, 21) observations.
Although none of the cell wall synthesis inhibitors inhibited PGL-I synthesis in the macrophages, cephalothin was reported to be active in the cell-free systems (8, 21), whereas D-cycloserine has been found to inhibit M. leprae in mice when used at high concentrations in feed (11) .
Among the nucleic acid synthesis inhibitors tested, the quinolone ciprofloxacin, although not found to be active in vivo (18) , inhibited PGL-I synthesis in the present study and also in the cell-free system (21) . Other quinolones, such as pefloxacin and ofloxacin, with better pharmacokinetics than ciprofloxacin have, however, been shown to be active against M. leprae in vivo (18, 19) . Although the antifungal agent griseofulvin was reported to inhibit PGL-I synthesis in the cell-free system (21) , it enhanced PGL-I synthesis in the macrophages.
The results of the present study correlate well with most in vivo observations reported in the literature. Certain drugs, such as rifampin, clofazimine, and erythromycin, tend to concentrate within phagocytic cells. This could explain the increased susceptibility of M. leprae to these drugs in the macrophages compared with the cell-free systems. Also, viable M. Ieprae exist within phagosomes in phagocytic cells (44) . Immediately following phagocytosis (15 to 20 min), phagosomes undergo acidification (10) , and the acidic pH within the phagosomes may contribute to the observed enhanced activity of some of the drugs in the macrophages compared with the cell-free system. For instance, while certain drugs such as ethionamide, rifabutin, and minocycline were shown to stimulate the synthesis of PGL-I in the cell-free system at neutral pH (20) , it has been recently observed that these drugs are inhibitory in that system at a pH of 5.5 (E. B. Harris, personal communication). The increased susceptibility to the drugs in the macrophages may also be due to an inhibitory effect of the drugs acting in concert with the host cell's microbicidal mechanisms. Rastogi et al. (37) compared the action of several drugs on some cultivable strains of mycobacteria residing either in a cell-free system or within macrophages. There were significant differences in the inhibitory concentrations of various antimicrobial agents between the two systems.
In conclusion, quantitation of PGL-I synthesis in macrophages has potential application to primary evaluation of new drugs against leprosy, and this procedure can be a useful tool for selecting potential antileprosy agents for further testing in the mouse footpad system prior to clinical evaluation.
